The Philadelphia chromosome is an abnormal, shortened chromosome 22 produced by an exchange of genetic material between chromosomes 9 and 22. This rearrangement creates the BCR::ABL1 fusion gene, which encodes an abnormally active signaling protein that promotes the growth and survival of blood-forming cells. It is the characteristic genetic abnormality of chronic myeloid leukemia (CML) and also occurs in a subset of acute leukemias. Its discovery established an important connection between a specific chromosomal abnormality and human cancer.
Chromosomal structure and formation
The Philadelphia chromosome usually results from a reciprocal chromosomal translocation, conventionally written as . In this notation, t indicates a translocation, the first pair of numbers identifies the chromosomes involved, and the remaining symbols identify regions on their long arms.
The rearrangement joins part of the BCR gene on chromosome 22 to part of the ABL1 gene on chromosome 9. The resulting fusion is generally located on the derivative chromosome 22—the Philadelphia chromosome. A reciprocal derivative chromosome 9 is also produced.
The names refer to related but distinct entities:
- Philadelphia chromosome describes the abnormal chromosome.
- BCR::ABL1 describes the fusion gene.
- BCR–ABL1 protein describes the fusion gene’s protein product.
This distinction matters because some cells contain BCR::ABL1 through a cryptic rearrangement that is not visible as a typical Philadelphia chromosome under conventional chromosome analysis. Variant translocations may involve additional chromosomes while still producing the same disease-driving fusion.
The rearrangement is an acquired, or somatic, alteration in a blood-forming cell rather than an inherited chromosome constitution present throughout the body. Descendants of the affected cell can carry the rearrangement, producing a population of genetically related cells.
Molecular mechanism
ABL1 normally encodes a tyrosine kinase, an enzyme that transfers phosphate groups to tyrosine residues in proteins. Its activity is regulated by interactions within the protein and by cellular signals.
Fusion to BCR changes this regulation. The BCR portion promotes association between fusion-protein molecules, helping maintain ABL1 kinase activity without the normal controls. The resulting protein activates multiple signaling pathways involved in proliferation, survival, adhesion, and interactions with the surrounding tissue.
These effects include stimulation of pathways such as RAS–MAPK, PI3K–AKT, and JAK–STAT, together with changes in the regulation of apoptosis. In CML, the abnormality arises in a hematopoietic stem cell or a closely related early blood-forming cell, allowing the affected clone to contribute to several blood-cell lineages.
BCR::ABL1 is a central driver of CML, but it does not alone explain every aspect of disease progression. Additional genetic and cellular changes contribute to the development of more aggressive disease.
Major fusion-protein forms
Different breakpoints and patterns of RNA splicing produce several BCR–ABL1 proteins. Their names indicate approximate molecular mass in kilodaltons.
| Protein form | Common associated transcripts | Typical association |
|---|---|---|
| p210 | e13a2 or e14a2 | The predominant form in CML; also found in some acute lymphoblastic leukemias |
| p190 | e1a2 | Common in Philadelphia-positive acute lymphoblastic leukemia; uncommon in CML |
| p230 | e19a2 | Rare; associated with some cases showing prominent neutrophilic differentiation |
These associations are not absolute. The fusion form alone does not establish a leukemia diagnosis.
Associated diseases
Chronic myeloid leukemia
CML is a myeloid blood cancer characterized by BCR::ABL1. It typically involves expansion of granulocytic cells and their precursors, often with an increased circulating white blood cell count. The fusion can be demonstrated in the great majority of cases through chromosome or molecular testing.
A small proportion have variant or cryptic rearrangements rather than the classic visible translocation. Conversely, a myeloid disorder lacking BCR::ABL1 is not classified as CML merely because it resembles CML in blood-cell appearance.
Acute lymphoblastic leukemia
The Philadelphia chromosome occurs in a subset of acute lymphoblastic leukemia (ALL), principally disease of B-cell lineage. Its frequency is higher in adults than in children.
Philadelphia-positive ALL and CML presenting in lymphoid blast phase can share the same fusion. Distinguishing them may require clinical history, blood and bone-marrow findings, immunophenotyping, and information about which cell lineages carry the rearrangement.
Philadelphia-like ALL, also called BCR::ABL1-like ALL, is a separate category. It has a gene-expression pattern resembling Philadelphia-positive ALL but lacks the BCR::ABL1 fusion.
Other acute leukemias
BCR::ABL1 can occur in rare cases of acute myeloid leukemia and mixed-phenotype acute leukemia. Interpretation requires particular care because advanced CML may also present as an acute leukemia.
Detection and monitoring
The Philadelphia chromosome and its molecular consequences can be assessed using complementary methods.
Conventional chromosome analysis. Examination of dividing cells reveals the translocation and other large-scale chromosome abnormalities. This form of cytogenetic analysis provides a broad view of the chromosome complement but may miss small or cryptic rearrangements.
Fluorescence in situ hybridization. Fluorescence in situ hybridization (FISH) uses labeled DNA probes to detect the juxtaposition of BCR and ABL1 sequences. It can examine nondividing cells and detect many rearrangements that are difficult to recognize by conventional chromosome analysis.
Reverse-transcription polymerase chain reaction. RNA is converted to complementary DNA, after which polymerase chain reaction amplifies the fusion sequence. Quantitative reverse-transcription PCR measures BCR::ABL1 transcript levels and is widely used to follow molecular response during CML treatment.
For common CML transcripts, results can be expressed on the International Scale, which supports comparison across appropriately standardized laboratories. A major molecular response corresponds to a BCR::ABL1 value of or less on this scale.
An undetectable result does not prove that every leukemic cell has disappeared. Its meaning depends on sample quality, assay sensitivity, and whether the method detects the patient’s particular transcript. Likewise, a transcript ratio is not simply the percentage of abnormal cells.
DNA sequencing and RNA-based sequencing methods can characterize unusual fusions and identify resistance-associated changes.
Therapeutic significance and limitations
BCR–ABL1 is a major example of a molecular target in cancer treatment. Tyrosine kinase inhibitors suppress its activity and have substantially changed the course of CML. Imatinib was the first widely used drug directed against this target; later agents include dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.
Most of these drugs bind in or near the ATP-binding site of ABL1. Asciminib instead binds an allosteric pocket involved in kinase regulation. In Philadelphia-positive ALL, BCR–ABL1 inhibitors are incorporated into treatment approaches that also address the acute leukemia.
The fusion is therefore both a disease-defining abnormality and a predictive biomarker for targeted treatment. Important limitations remain:
- Kinase-domain mutations can reduce sensitivity to particular inhibitors.
- Leukemic stem cells may persist despite strong suppression of BCR–ABL1 activity.
- Additional abnormalities and alternative signaling mechanisms can contribute to progression or resistance.
- Molecular findings require interpretation alongside clinical and laboratory evidence.
Discovery and historical importance
Peter Nowell and David Hungerford reported the abnormal chromosome in 1960 while studying cells from people with CML in Philadelphia, Pennsylvania. The chromosome was named after the city.
In 1973, Janet Rowley demonstrated that it resulted from a translocation between chromosomes 9 and 22, rather than a simple loss of chromosome material. Subsequent molecular research identified BCR::ABL1 and established the abnormal kinase activity of its protein product.
The sequence from chromosome discovery to fusion-gene characterization and targeted drug development became a foundational example of how a cancer-associated genetic alteration can reveal a disease mechanism and provide a therapeutic target.